Extracted RNA was linearly amplified using the RiboAmp RNA Amplification kit (Molecular Devices, Sunnyvale, CA)

Extracted RNA was linearly amplified using the RiboAmp RNA Amplification kit (Molecular Devices, Sunnyvale, CA). proteomic profiling revealed significant variations in salivary molecular biomarkers between breast cancer patients and matched controls. Eight mRNA biomarkers and one protein biomarker, which were not affected by the confounding factors, were pre-validated, yielding an accuracy of 92% (83% sensitive, 97% specific) around the preclinical validation sample set. == Conclusions == Our findings support that transcriptomic and proteomic signatures in saliva can serve as biomarkers for the non-invasive detection of breast cancer. The salivary biomarkers possess discriminatory power for the detection of breast cancer, with high specificity and sensitivity, which paves the way for prediction model validation study followed by pivotal clinical validation. == Introduction == Early detection of breast cancer is the key to positive, long-lasting outcomes, thus reducing the suffering and cost to society associated with the disease[1]. The high burden of breast cancer in women worldwide underscores the unmet potential of biomarker for early detection. A significant obstacle towards early detection of breast cancer is the development of methods that efficiently and accurately identify potentially affected individuals[2],[3]. Breast cancer has been among the earliest and most intensely-studied diseases using gene expression profiling and protein profiling technologies. The resulting molecular signatures help reveal the biological spectrum of breast cancers, providing diagnostic tools as well as prognostic and predictive gene signatures[4],[5]. Breast cancer detection is currently based on physical examination and imaging (mammography, ultrasound, and MRI)[6], although emerging methods include direct examination of the cytomorphology of exfoliated cells[7], and the molecular analysis of tumor biomarkers in nipple aspirate fluid or in ductal lavage[8],[9],[10]. In the last decade, biomarker discoveries for breast cancer detection have focused UNC0321 on blood and/or tissue, using proteomic[11],[12],[13],[14],[15],[16], transcriptomic[17],[18],[19],[20],[21], and genomic approaches[22],[23]. In comparison to prognostic biomarkers[24],[25],[26], the development of detection Rabbit polyclonal to HYAL2 biomarkers has been limited, mainly due to a lack of sensitivity and specificity for this clinical context[2],[27],[28]. Most importantly, the use of tissue biomarkers for early detection will be limited to patients at very high risk because they rely on invasive procedures. Recently, the study of salivary biomarkers has developed beyond oral diseases[29],[30],[31],[32]to systemic diseases[33],[34], broadening the potential for systemic disease detection[35],[36],[37],[38],[39]. Saliva-based translational research and technology is now at a mature juncture and can be evaluated to determine its utility for breast cancer detection. Explorative studies have evaluated the potential use of salivary proteins such as c-erbB-2, VEGF, EGF, and CEA in the initial detection and/or follow-up screening for the recurrence of breast UNC0321 cancer[33],[40],[41],[42],[43],[44]. However, these investigations were not based on biomarker discoveries from saliva specimens, rather they were testing blood biomarkers in saliva[45]. Here, we report the use of transcriptomic and proteomic approaches to discover and pre-validate biomarkers in saliva for the non-invasive detection of breast cancer. Our results demonstrate significant differences in salivary transcriptomic and proteomic profiles between breast cancer patients and controls. The discovered salivary biomarkers possess discriminatory power for the detection of breast cancer, with high specificity and sensitivity. == Results == == Variation of salivary gene expression profiles and identification of mRNA biomarkers == Schematic of the study design and demographic information of all subjects used UNC0321 for the discovery and pre-validation phases are shown inFigure 1andTable 1, respectively. Transcriptomic profiling identified 1402 genes exhibiting >2 fold up-regulation, and 2247 genes exhibiting >2 fold down-regulation, in the saliva of breast.